Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease (ESRD)
Vascular Access Complication

Interventions

BIOLOGICAL: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)
DRUG: Placebo
BIOLOGICAL: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)

Sponsor

Mayo Clinic